The term ‘anti-cancer medicines’ includes conventional cytotoxic and cytostatic medicines, as well as newer biological treatments such as monoclonal antibodies, so-called ‘small molecules’, and other targeted therapies. The national Patient Safety Agency in the UK review 4,829 incident reports reported between 1 November 2003 and 30 June 2008 and identified common causes of error with these medicines and ways that these risks can be better managed. Read the report here.